Starting in 2027, prices for 15 high-cost Medicare Part D drugs, including treatments for cancer, diabetes, and respiratory diseases, will be significantly reduced by about 44%. This second round of price negotiations under the Inflation Reduction Act is expected to save Medicare $12 billion and beneficiaries $685 million in out-of-pocket costs. The program aims to improve drug affordability and access for millions of Medicare patients.
Continue to full article
Leave a Reply